Company: HURA
Filing Date: 2025-11-03
Form Type: S-3
Source: 0001193125-25-262843
Chunk: 59

Company: TuHURA Biosciences, Inc./NV
Filing Date: 2025-11-03
Form: S-3
Chunk 59
---
 may not use the proceeds effectively.

Our
management will have broad discretion as to the application of the net proceeds from this offering and could use them for purposes other than those contemplated at the time of this offering. Our stockholders may not agree with the manner in which
our management chooses to allocate and spend the net proceeds. Moreover, our management may use the net proceeds for corporate purposes that may not positively impact our results of operations or increase the market value of our Common Stock. Our
failure to apply these funds effectively could have a material adverse effect on our business, delay the development of our products and/or cause the price of our Common Stock to decline.

If we raise additional capital in the future, your ownership in us could be diluted.

In order to raise additional capital, we may at any time, including during this offering, offer additional shares of Common Stock or other
securities convertible into or exchangeable for our Common Stock at prices that may not be the same as the price per share in this offering. We may sell shares or other securities in any other offering at a price per share that is less than the
price per share paid by investors in this offering, and investors purchasing shares or other securities in the future could have rights superior to existing stockholders, including investors who purchase Common Stock in this offering. The price per
share at which we sell additional shares of Common Stock or securities convertible into Common Stock in future transactions may be higher or lower than the price per share in this offering.

Until such time, if ever, as we can generate substantial revenue from our operations, we anticipate financing our cash needs through a
combination of equity offerings, debt financings and license agreements. To the extent that we raise additional capital through the further sale of equity securities or convertible debt securities, your ownership interest will be diluted.

Sales of a substantial number of our shares of Common Stock in the public market could cause our stock price to fall.

We may issue and sell additional shares of Common Stock in the public markets, including during this offering. As a result, a substantial
number of shares of our Common Stock may be sold in the public market. Sales of a substantial number of shares of our Common Stock in the public markets, including during this offering, or the perception that such sales could occur, could depress
the market price of our Common Stock and impair our ability to raise capital through the sale of additional equity securities.

S-6

Because we do not currently intend to declare cash dividends on our shares of Common Stock in the foreseeable future,